On May 5, 2026 AVEO Oncology, an LG Chem company ("AVEO"), reported that two abstracts were accepted for presentation at the upcoming American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2026 annual meeting this May 29-June 2, 2026, in Chicago, IL.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details

Title: Final analysis of the TiNivo-2 phase 3 trial: Long-term outcome of tivozanib (Tivo) in patients with metastatic renal cell carcinoma (mRCC)
First Author: Robert Motzer, MD, Memorial Sloan Kettering Cancer Center
Abstract Number: 4555
Poster Session: Genitourinary Cancer—Kidney and Bladder
Poster Board: 34
Date and Time: Sunday, May 31, 2026, 9:00am – 12:00 PM CDT

Title: FIERCE-HN: A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of ficlatuzumab (HGF/cMET mAb) in combination with cetuximab in participants with recurrent or metastatic (R/M) HPV negative head and neck squamous cell carcinoma (HNSCC)
First Author: Julie E. Bauman, MD, MPH, George Washington University Cancer Center
Abstract Number: TPS6132
Poster Session: Head and Neck Cancer
Poster Board: 585b
Date and Time: Saturday, May 30, 2026, 1:30 PM – 4:30 PM CDT

(Press release, AVEO, MAY 5, 2026, View Source [SID1234665148])